Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-31190781

RESUMEN

Purpose: Clinically important deterioration (CID) in chronic obstructive pulmonary disease (COPD) is a novel composite endpoint that assesses disease stability. The association between short-term CID and future economic and quality of life (QoL) outcomes has not been previously assessed. This analysis considers 3-year data from the TOwards a Revolution in COPD Health (TORCH) study, to examine this question. Patients and methods: This post hoc analysis of TORCH (NCT00268216) compared costs and utilities at 3 years among patients without CID (CID-) and with CID (CID+) at 24 weeks. A positive CID status was defined as either: a deterioration in forced expiratory volume in 1 second (FEV1) of ≥100 mL from baseline; or a ≥4-unit increase from baseline in St George's Respiratory Questionnaire (SGRQ) total score; or the incidence of a moderate/severe exacerbation. Patients from all treatment arms were included. Utility change was based on the EQ-5D utility index. Costs were based on healthcare resource utilization from 24 weeks to end of follow-up combined with unit costs for the UK (2016 GBP), and reported as per patient per year (PPPY). Adjusted estimates were generated controlling for baseline characteristics, treatment assignment, and number of CID criteria met. Results: Overall, 3,769 patients completed the study and were included in the analysis (stable CID- patients, n=1,832; unstable CID+ patients, n=1,937). At the end of follow-up, CID- patients had higher mean (95% confidence interval [CI]) utility scores than CID+ patients (0.752 [0.738, 0.765] vs 0.697 [0.685, 0.71]; difference +0.054; P<0.001), and lower costs PPPY (£538 vs £916; difference: £378 [95% CI: £244, £521]; P<0.001). The cost differential was primarily driven by the difference in general hospital ward days (P=0.003). Conclusion: This study demonstrated that achieving early stability in COPD by preventing short-term CID is associated with better preservation of future QoL alongside reduced healthcare service costs.


Asunto(s)
Broncodilatadores/economía , Broncodilatadores/uso terapéutico , Combinación Fluticasona-Salmeterol/economía , Combinación Fluticasona-Salmeterol/uso terapéutico , Glucocorticoides/economía , Glucocorticoides/uso terapéutico , Costos de la Atención en Salud , Pulmón/efectos de los fármacos , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Anciano , Ahorro de Costo , Análisis Costo-Beneficio , Progresión de la Enfermedad , Método Doble Ciego , Femenino , Volumen Espiratorio Forzado , Humanos , Pulmón/fisiopatología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Calidad de Vida , Factores de Tiempo , Resultado del Tratamiento
2.
Singapore Med J ; 59(7): 383-389, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29546433

RESUMEN

INTRODUCTION: In light of the growing evidence base for better clinical results with the use of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) over inhaled corticosteroid-containing salmeterol/fluticasone combination (SFC), this study aimed to evaluate the cost-effectiveness of IND/GLY over SFC in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are at low risk of exacerbations, in the Singapore healthcare setting. METHODS: A previously published patient-level simulation model was adapted for use in Singapore by applying local unit costs. The model was populated with clinical data from the LANTERN and ECLIPSE studies. Both costs and health outcomes were predicted for the lifetime horizon from a payer's perspective and were discounted at 3% per annum. Costs were expressed in 2015 USD exchange rates. Uncertainty was assessed through probabilistic sensitivity analysis. RESULTS: Compared to SFC, use of IND/GLY increased mean life expectancy by 0.316 years and mean quality-adjusted life years (QALYs) by 0.246 years, and decreased mean total treatment costs (drug costs and management of associated events) by USD 1,474 over the entire lifetime horizon. IND/GLY was considered to be 100% cost-effective at a threshold of 1 × gross domestic product per capita. The cost-effectiveness acceptability curve showed that IND/GLY was 100% cost-effective at a willingness-to-pay threshold of USD 0 (additional cost) when compared to SFC. CONCLUSION: IND/GLY was estimated to be highly cost-effective compared to SFC in patients with moderate-to-severe COPD who are not at high risk of exacerbations in the Singapore healthcare setting.


Asunto(s)
Combinación Fluticasona-Salmeterol/economía , Glicopirrolato/economía , Indanos/economía , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/economía , Quinolonas/economía , Anciano , Broncodilatadores , Estudios de Cohortes , Simulación por Computador , Análisis Costo-Beneficio , Combinación de Medicamentos , Costos de los Medicamentos , Femenino , Combinación Fluticasona-Salmeterol/administración & dosificación , Volumen Espiratorio Forzado , Glicopirrolato/administración & dosificación , Hospitales , Humanos , Indanos/administración & dosificación , Masculino , Persona de Mediana Edad , Probabilidad , Años de Vida Ajustados por Calidad de Vida , Quinolonas/administración & dosificación , Singapur/epidemiología
3.
J Med Econ ; 21(6): 629-638, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29577787

RESUMEN

AIMS: To examine the clinical and economic outcomes associated with the use of long-acting bronchodilators for initial maintenance treatment of chronic obstructive pulmonary disease (COPD) by analyzing health insurance claims data in the US. METHODS: A retrospective, observational, matched cohort study used health insurance claims data (January 2008 to June 2013) to assess COPD-related outcomes for subjects aged ≥40 years. Subjects were assigned to a study cohort according to the first observed prescription fill for a long-acting bronchodilator (fluticasone propionate 250 mcg/salmeterol 50 mcg [FSC] or tiotropium bromide 18 mcg [TIO]). The analysis period for each subject comprised a 1-year pre-index date and 1-year post-index date. Primary outcome measure was total COPD-related costs per-patient per-year (PPPY) during the follow-up period. Secondary outcome measures included COPD-related exacerbations and the components of COPD-related costs. RESULTS: Overall, 24,040 subjects were identified; the analysis sample consisted of 19,090 subjects (9,545 per cohort) with no significant differences between cohorts. Mean COPD-related total costs PPPY were numerically lower among the FSC cohort; however, the difference was not statistically significant ($2,224 [±4,108] vs $2,352 [±3,721], p = .057). There was no difference between cohorts for COPD-related medical costs (p = .894). COPD-related pharmacy costs were significantly, yet modestly, lower in the FSC cohort compared with the TIO cohort ($1,160 [±1,106] vs 1,275 [±1,110], p < .001). There were no statistically significant differences in the rate or number of exacerbations between the matched cohorts. LIMITATIONS: While propensity scoring achieved balance in baseline characteristics, some residual confounding unobserved in the database may be present. CONCLUSIONS: Few clinical and economic differences between subjects initiating maintenance therapy with FSC or TIO were observed.


Asunto(s)
Broncodilatadores/uso terapéutico , Combinación Fluticasona-Salmeterol/uso terapéutico , Gastos en Salud/estadística & datos numéricos , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Bromuro de Tiotropio/uso terapéutico , Factores de Edad , Anciano , Anciano de 80 o más Años , Broncodilatadores/economía , Combinación de Medicamentos , Femenino , Combinación Fluticasona-Salmeterol/economía , Humanos , Revisión de Utilización de Seguros , Masculino , Programas Controlados de Atención en Salud/estadística & datos numéricos , Persona de Mediana Edad , Modelos Econométricos , Características de la Residencia , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Factores Sexuales , Bromuro de Tiotropio/economía
4.
Respir Res ; 18(1): 206, 2017 12 11.
Artículo en Inglés | MEDLINE | ID: mdl-29228950

RESUMEN

BACKGROUND: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. METHODS: A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer's perspective and were discounted at 3% annually. Uncertainty in model input values was studied through one-way and probabilistic sensitivity analyses. Subgroup analyses were also performed. RESULTS: IND/GLY was associated with lower costs and better outcomes compared with SFC over all the analysed time horizons. Use of IND/GLY resulted in additional 0.192 LYs and 0.134 QALYs with cost savings of €1211 compared with SFC over lifetime. The net monetary benefit (NMB) was estimated to be €8560 based on a willingness-to-pay threshold of €55,000/QALY. The NMB was higher in the following subgroups: severe (GOLD 3), high risk and more symptoms (GOLD D), females, and current smokers. CONCLUSION: IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year.


Asunto(s)
Análisis Costo-Beneficio/métodos , Combinación Fluticasona-Salmeterol/economía , Glicopirrolato/economía , Indanos/economía , Modelos Económicos , Vigilancia de la Población/métodos , Enfermedad Pulmonar Obstructiva Crónica/economía , Quinolonas/economía , Anciano , Método Doble Ciego , Combinación de Medicamentos , Femenino , Combinación Fluticasona-Salmeterol/administración & dosificación , Glicopirrolato/administración & dosificación , Humanos , Indanos/administración & dosificación , Masculino , Persona de Mediana Edad , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Quinolonas/administración & dosificación , Suecia/epidemiología
5.
BMC Pulm Med ; 17(1): 179, 2017 Dec 08.
Artículo en Inglés | MEDLINE | ID: mdl-29216852

RESUMEN

BACKGROUND: Equitable access to affordable medicines and diagnostic tests is an integral component of optimal clinical care of patients with asthma and chronic obstructive pulmonary disease (COPD). In Uganda, we lack contemporary data about the availability, cost and affordability of medicines and diagnostic tests essential in asthma and COPD management. METHODS: Data on the availability, cost and affordability of 17 medicines and 2 diagnostic tests essential in asthma and COPD management were collected from 22 public hospitals, 23 private and 85 private pharmacies. The percentage of the available medicines and diagnostic tests, the median retail price of the lowest priced generic brand and affordability in terms of the number of days' wages it would cost the least paid public servant were analysed. RESULTS: The availability of inhaled short acting beta agonists (SABA), oral leukotriene receptor antagonists (LTRA), inhaled LABA-ICS combinations and inhaled corticosteroids (ICS) in all the study sites was 75%, 60.8%, 46.9% and 45.4% respectively. None of the study sites had inhaled long acting anti muscarinic agents (LAMA) and inhaled long acting beta agonist (LABA)-LAMA combinations. Spirometry and peak flow-metry as diagnostic tests were available in 24.4% and 6.7% of the study sites respectively. Affordability ranged from 2.2 days' wages for inhaled salbutamol to 17.1 days' wages for formoterol/budesonide inhalers and 27.8 days' wages for spirometry. CONCLUSION: Medicines and diagnostic tests essential in asthma and COPD care are not widely available in Uganda and remain largely unaffordable. Strategies to improve access to affordable asthma and COPD medicines and diagnostic tests should be implemented in Uganda.


Asunto(s)
Corticoesteroides/provisión & distribución , Agonistas Adrenérgicos beta/provisión & distribución , Asma/tratamiento farmacológico , Técnicas de Diagnóstico del Sistema Respiratorio/estadística & datos numéricos , Accesibilidad a los Servicios de Salud , Antagonistas de Leucotrieno/provisión & distribución , Antagonistas Muscarínicos/provisión & distribución , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Administración por Inhalación , Corticoesteroides/economía , Corticoesteroides/uso terapéutico , Agonistas Adrenérgicos beta/economía , Agonistas Adrenérgicos beta/uso terapéutico , Albuterol/economía , Albuterol/provisión & distribución , Albuterol/uso terapéutico , Antiasmáticos/provisión & distribución , Antiasmáticos/uso terapéutico , Asma/diagnóstico , Combinación Budesonida y Fumarato de Formoterol/economía , Combinación Budesonida y Fumarato de Formoterol/provisión & distribución , Combinación Budesonida y Fumarato de Formoterol/uso terapéutico , Combinación de Medicamentos , Costos de los Medicamentos , Combinación Fluticasona-Salmeterol/economía , Combinación Fluticasona-Salmeterol/provisión & distribución , Combinación Fluticasona-Salmeterol/uso terapéutico , Humanos , Antagonistas de Leucotrieno/economía , Antagonistas de Leucotrieno/uso terapéutico , Antagonistas Muscarínicos/economía , Antagonistas Muscarínicos/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Pruebas de Función Respiratoria , Espirometría , Uganda
6.
Respir Med ; 129: 199-206, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28732831

RESUMEN

OBJECTIVE: Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment could positively influence the economic burden of this disease. Fluticasone propionate/Formoterol (FP/FOR) may be as effective as Fluticasone Salmeterol (FP/SAL). We evaluated non-inferiority of asthma control in terms of the proportion of patients free from exacerbations, and conducted a cost impact analysis. METHODS: This historical, matched cohort database study evaluated two treatment groups in the Optimum Patient Care Research Database in the UK: 1) an FP/FOR cohort of patients initiating treatment with FP/FOR or changing from FP/SAL to FP/FOR and; 2) an FP/SAL cohort comprising patients initiating, or remaining on FP/SAL pMDI combination therapy. The main outcome evaluated non-inferiority of effectiveness (defined as prevention of severe exacerbations, lower limit of the 95% confidence interval (CI) of the mean difference between groups in patient proportions with no exacerbations is -3.5% or higher) in patients treated with FP/FOR versus FP/SAL. RESULTS: After matching 1:3, we studied a total of 2472 patients: 618 in the FP/FOR cohort (174 patients initiated on FP/FOR and 444 patients changed to FP/FOR) and 1854 in the FP/SAL cohort (522 patients initiated FP/SAL and 1332 continued FP/SAL). The percentage of patients prescribed FP/FOR met non-inferiority as the adjusted mean difference in proportion of no severe exacerbations (95%CI) was 0.008 (-0.032, 0.047) between the two cohorts. No other significant differences were observed except acute respiratory event rates, which were lower for patients prescribed FP/FOR (rate ratio [RR] 0.82, 95% CI 0.71, 0.94). CONCLUSIONS: Changing to, or initiating FP/FOR combination therapy, is associated with a non-inferior proportion of patients who are severe exacerbation-free at a lower average annual cost compared with continuing or initiating treatment with FP/SAL.


Asunto(s)
Androstadienos/uso terapéutico , Antiasmáticos/economía , Asma/tratamiento farmacológico , Asma/economía , Estudios de Cohortes , Análisis Costo-Beneficio/economía , Quimioterapia Combinada/métodos , Etanolaminas/uso terapéutico , Combinación Fluticasona-Salmeterol/uso terapéutico , Adulto , Anciano , Androstadienos/administración & dosificación , Androstadienos/economía , Antiasmáticos/uso terapéutico , Combinación de Medicamentos , Etanolaminas/administración & dosificación , Etanolaminas/economía , Femenino , Fluticasona , Combinación Fluticasona-Salmeterol/administración & dosificación , Combinación Fluticasona-Salmeterol/economía , Fumarato de Formoterol , Humanos , Masculino , Persona de Mediana Edad , Aceptación de la Atención de Salud/estadística & datos numéricos , Calidad de Vida , Resultado del Tratamiento , Reino Unido/epidemiología
7.
Int J Chron Obstruct Pulmon Dis ; 11: 2749-2755, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27853362

RESUMEN

AIM: The objective of this study was to evaluate the different outcomes associated with the use of budesonide/formoterol compared to fluticasone/salmeterol in fixed combinations in patients with COPD in a "real-world" setting. The outcomes included exacerbation rates and health care costs. PATIENTS AND METHODS: An observational retrospective cohort analysis, based on administrative databases of three local health units, was conducted. Patients with at least one prescription of fixed-dose combination of inhaled corticosteroids and long-acting ß2-agonists (budesonide/formoterol or fluticasone/salmeterol), at dosages and formulations approved for COPD in Italy, between January 1, 2009 and December 31, 2011 (inclusion period), were included. Patients were followed until December 2012, death or end of treatment (follow-up period), whichever occurred first. Patients were included if they were aged ≥40 years and had at least 6 months of follow-up. Propensity score matching was performed to check for confounding effects. Number of hospitalizations for COPD and number of oral corticosteroid and antibiotic prescriptions during follow-up were analyzed using Poisson regression models. The cost analysis was conducted from the perspective of the National Health System. RESULTS: After matching, 4,680 patients were analyzed, of which 50% were males with a mean age of 64±13 years. In the Poisson regression models, the incidence rate ratio for budesonide/formoterol as compared to fluticasone/salmeterol was 0.84 (95% confidence interval [CI]: 0.74-0.96, P=0.010) for number of hospitalizations, 0.89 (95% CI: 0.87-0.92, P<0.001) for number of oral corticosteroid prescriptions and 0.88 (95% CI: 0.86-0.89, P<0.001) for number of antibiotic prescriptions. The mean annual expenditure for COPD management was €2,436 for patients treated with budesonide/formoterol and €2,784 for patients treated with fluticasone/salmeterol. CONCLUSION: Among patients with COPD, treatment with a fixed combination of budesonide/formoterol was associated with fewer exacerbations and a lower, but not significant, cost of illness than the treatment with fluticasone/salmeterol. Real-world analyses are requested to ameliorate interventions to address unmet needs, optimizing treatment pathways to improve COPD-related burden and outcomes.


Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Broncodilatadores/uso terapéutico , Combinación Budesonida y Fumarato de Formoterol/uso terapéutico , Combinación Fluticasona-Salmeterol/uso terapéutico , Glucocorticoides/uso terapéutico , Pulmón/efectos de los fármacos , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Reclamos Administrativos en el Cuidado de la Salud , Agonistas de Receptores Adrenérgicos beta 2/efectos adversos , Agonistas de Receptores Adrenérgicos beta 2/economía , Anciano , Broncodilatadores/efectos adversos , Broncodilatadores/economía , Combinación Budesonida y Fumarato de Formoterol/efectos adversos , Combinación Budesonida y Fumarato de Formoterol/economía , Análisis Costo-Beneficio , Bases de Datos Factuales , Progresión de la Enfermedad , Costos de los Medicamentos , Femenino , Combinación Fluticasona-Salmeterol/efectos adversos , Combinación Fluticasona-Salmeterol/economía , Glucocorticoides/efectos adversos , Glucocorticoides/economía , Humanos , Italia , Pulmón/fisiopatología , Masculino , Persona de Mediana Edad , Puntaje de Propensión , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/economía , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Recuperación de la Función , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento
8.
Adv Ther ; 33(5): 794-806, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-27084726

RESUMEN

INTRODUCTION: Pressurized metered-dose inhalers (pMDI) such as fluticasone propionate and salmeterol (FP/SAL) are commonly used for the treatment of asthma in the UK. Previously, a budget impact analysis demonstrated that use of FP and formoterol fumarate (FP/FORM) pMDI as an alternative to FP/SAL pMDI, would be a cost-saving option for the UK National Health Service (NHS). This budget impact analysis aimed to update the existing analysis with prescription volume data and real-world evidence since the introduction of FP/FORM to the UK market. METHODS: Patient Data (IMS Information Solutions UK Ltd) moving annual total (MAT) August 2015 were used to ascertain the number of units of pMDI prescribed. Annual costs to the NHS in terms of drug, administration, monitoring and adverse event costs, were used to estimate the potential budget impact for FP/FORM and FP/SAL. Costs were calculated for current prescription volumes (12% FP/FORM, 88% FP/SAL), and for different prescription volume scenarios (FP/FORM at 0%, 25%, 50% and 100%). Real-world evidence and budget impact at a clinical commissioning group (CCG) level were also considered. RESULTS: Total annual costs per person year were less with FP/FORM (£625) than with FP/SAL (£734). Annual costs to the NHS based on the current prescription volumes and clinical trial data were estimated at £210.0M, however, based on real-world evidence, costs were estimated at £179.8M. For all scenarios with increased FP/FORM prescription volumes, the annual total costs to the NHS decreased. This was reflected at a CCG level. CONCLUSION: The use of FP/FORM as an alternative to FP/SAL can result in cost savings for the NHS when assessing drug, administration, monitoring and adverse events costs. The inclusion of data released since the launch of FP/FORM within the budget impact analysis demonstrates that the potential cost savings to the NHS that were previously published are being translated to clinical practice. FUNDING: Mundipharma, UK.


Asunto(s)
Asma , Ahorro de Costo/métodos , Combinación Fluticasona-Salmeterol , Fumarato de Formoterol , Asma/tratamiento farmacológico , Asma/economía , Monitoreo de Drogas/métodos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Combinación Fluticasona-Salmeterol/economía , Combinación Fluticasona-Salmeterol/farmacología , Fumarato de Formoterol/economía , Fumarato de Formoterol/farmacología , Evaluación del Impacto en la Salud , Humanos , Inhaladores de Dosis Medida , Modelos Económicos , Medicina Estatal , Reino Unido
9.
J Manag Care Spec Pharm ; 22(3): 293-304, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27003559

RESUMEN

BACKGROUND: Chronic obstructive pulmonary disease (COPD) affects approximately 15 million people in the United States and accounts for approximately $36 billion in economic burden, primarily due to medical costs. To address the increasing clinical and economic burden, the Global Initiative for Chronic Obstructive Lung Disease emphasizes the use of therapies that help prevent COPD exacerbations, including inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA). OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system. METHODS: COPD patients aged 40 years and older who initiated BFC (160/4.5 µg) or FSC (250/50 µg) treatment between March 1, 2009, and March 31, 2012, were identified using claims data from major U.S. health plans. BFC and FSC patients were propensity score matched (1:1) on age, sex, prior asthma diagnosis, prior COPD-related health care utilization, and respiratory medication use. COPD-related, pneumonia-related, and all-cause costs and utilization were analyzed during the 12-month follow-up period. Post-index costs were assessed with generalized linear models (GLMs) with gamma distribution. Health care utilization data were analyzed via logistic regression (any event vs. none) and GLMs with negative binomial distribution (number of visits) and were adjusted for the analogous pre-index variable as well as pre-index characteristics that remained imbalanced after matching. RESULTS: After matching, each cohort had 3,697 patients balanced on age (mean 64 years), sex (female 52% BFC and 54% FSC), asthma and other comorbid conditions, prior COPD-related health care utilization, and respiratory medication use. During the 12-month follow-up, COPD-related costs averaged $316 less for BFC versus FSC patients ($4,326 vs. $4,846; P = 0.003), reflecting lower inpatient ($966 vs. $1,202; P < 0.001), pharmacy ($1,482 vs. $1,609; P = 0.002), and outpatient/office ($1,378 vs. $1,436; P = 0.048) costs, but higher emergency department ($257 vs. $252; P = 0.033) costs. Pneumonia-related health care costs were also lower on average for BFC patients ($2,855 vs. $3,605; P < 0.001). Similarly, initiating BFC was associated with lower all-use health care costs versus initiating FSC ($21,580 vs. $24,483; P < 0.001, respectively). No differences in health care utilization were found between the 2 groups. CONCLUSIONS: In this study, although no difference was observed in rates of health care utilization, COPD patients initiating BFC treatment incurred lower average COPD-related, pneumonia-related, and all-cause costs versus FSC initiators, which was driven by cumulative differences in inpatient, outpatient, and pharmacy costs.


Asunto(s)
Budesonida/economía , Quimioterapia Combinada/economía , Combinación Fluticasona-Salmeterol/economía , Fumarato de Formoterol/economía , Costos de la Atención en Salud , Aceptación de la Atención de Salud , Enfermedad Pulmonar Obstructiva Crónica/economía , Corticoesteroides/administración & dosificación , Agonistas de Receptores Adrenérgicos beta 2/administración & dosificación , Anciano , Asma/tratamiento farmacológico , Asma/economía , Broncodilatadores/administración & dosificación , Broncodilatadores/economía , Budesonida/administración & dosificación , Quimioterapia Combinada/métodos , Femenino , Combinación Fluticasona-Salmeterol/administración & dosificación , Fumarato de Formoterol/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Estudios Retrospectivos , Estados Unidos
10.
Artículo en Inglés | MEDLINE | ID: mdl-26839089

RESUMEN

This review identifies and evaluates the comprehensive reporting of peer-reviewed economic evaluations of the effectiveness of fluticasone-propionate/salmeterol combination (FSC) therapy for maintenance treatment of chronic obstructive pulmonary disease (COPD). Economic evaluations were included if published in English since 2003. Evaluation categories included in the review were cost-effectiveness, cost-utility, and cost-consequence analyses. FSC is cost-effective in comparison to short-acting bronchodilators (SABDs). Cost and outcome differences between FSC and other long-acting therapies were modest. Studies exhibited large variations in populations, designs and environment, limiting the ability to draw conclusions. Many new maintenance treatments for COPD have been approved since 2010. Most have yet to be compared to older treatments like FSC. Evaluations are needed that consider costs and outcomes from a societal perspective (e.g., patients' ability to keep working) and evaluations that include subgroup analyses to investigate differential impacts according to clusters of patient characteristics.


Asunto(s)
Combinación Fluticasona-Salmeterol/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Broncodilatadores/economía , Broncodilatadores/uso terapéutico , Análisis Costo-Beneficio , Combinación Fluticasona-Salmeterol/economía , Humanos , Enfermedad Pulmonar Obstructiva Crónica/economía , Resultado del Tratamiento
11.
Artículo en Inglés | MEDLINE | ID: mdl-25926729

RESUMEN

Chronic obstructive pulmonary disease (COPD) and asthma are common airway disorders characterized by chronic airway inflammation and airflow obstruction, and are a leading cause of morbidity and mortality in the People's Republic of China. These two diseases pose a high economic burden on the family and the whole of society. Despite evidence-based Global Initiative for Chronic Obstructive Lung Disease and Global Initiative for Asthma guidelines being available for the diagnosis and management of COPD and asthma, many of these patients are not properly diagnosed or managed in the People's Republic of China. The value of combination therapy with inhaled corticosteroids and long-acting ß2-agonists has been established in the management of asthma and COPD globally. Combinations of inhaled corticosteroids and long-acting ß2-agonists such as fluticasone and salmeterol, have been shown to be effective for improving symptoms, health status, and reducing exacerbations in both diseases. In this review, we discuss the efficacy and safety of this combination therapy from key studies, particularly in the People's Republic of China.


Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Combinación Fluticasona-Salmeterol/uso terapéutico , Glucocorticoides/uso terapéutico , Pulmón/efectos de los fármacos , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Administración por Inhalación , Agonistas de Receptores Adrenérgicos beta 2/administración & dosificación , Agonistas de Receptores Adrenérgicos beta 2/efectos adversos , Agonistas de Receptores Adrenérgicos beta 2/economía , Adulto , Pueblo Asiatico , Asma/diagnóstico , Asma/economía , Asma/etnología , Asma/fisiopatología , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Broncodilatadores/economía , China/epidemiología , Análisis Costo-Beneficio , Costos de los Medicamentos , Combinación Fluticasona-Salmeterol/administración & dosificación , Combinación Fluticasona-Salmeterol/efectos adversos , Combinación Fluticasona-Salmeterol/economía , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Glucocorticoides/economía , Humanos , Pulmón/fisiopatología , Nebulizadores y Vaporizadores , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/economía , Enfermedad Pulmonar Obstructiva Crónica/etnología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...